{
  "ticker": "LLY",
  "target_date": "2025-09-22",
  "actual_date": "2025-09-22",
  "collected_at": "2025-12-08T12:18:35.010095",
  "price": {
    "open": 747.46,
    "high": 760.92,
    "low": 745.18,
    "close": 753.8428955078125,
    "volume": 2527400,
    "change_1d_pct": 0.39,
    "change_7d_pct": -0.18,
    "change_30d_pct": 20.93
  },
  "technicals": {
    "rsi_14": 60.04,
    "sma_20": 742.49,
    "sma_50": 737.17,
    "macd": 8.688,
    "macd_signal": 6.893,
    "macd_histogram": 1.795,
    "bb_upper": 774.61,
    "bb_lower": 710.38,
    "price_vs_sma20_pct": 1.53,
    "price_vs_sma50_pct": 2.26,
    "volume_ratio": 0.72
  },
  "fundamentals": {
    "market_cap": 892602023936,
    "pe_ratio": 48.784912,
    "forward_pe": 43.940865,
    "price_to_book": 37.488705,
    "price_to_sales": 15.021963,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.46,
    "pct_from_52w_low": 59.62
  },
  "macro": {
    "spy": {
      "price": 666.84,
      "change_1d_pct": 0.47,
      "change_7d_pct": 1.72
    },
    "vix": {
      "level": 16.1,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.14
    },
    "dollar_index": {
      "level": 97.33
    },
    "gold": {
      "price": 3740.7
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Analysis: Innovent's weight-loss drug highlights China challenge for Novo, Lilly",
      "source": "Yahoo",
      "datetime": 1758582195,
      "summary": "SHANGHAI (Reuters) -Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining traction.  Xinermei, launched in July, is the third once-weekly injectable GLP-1 we",
      "url": "https://finnhub.io/api/news?id=360aea5887bf62337dddef0d530308f973e0d52e1900159d14cf71458cc98a9d"
    },
    {
      "headline": "Pfizer joining GLP-1 race: How Novo & Eli Lilly compare",
      "source": "Yahoo",
      "datetime": 1758574800,
      "summary": "Pfizer (PFE) is entering the weight-loss drug race with its acquisition of Metsera. BMO Capital Markets managing director of biopharma equity research Evan Seigerman Yahoo Finance Head of News Myles Udland on Market Domination to discuss how investors can play the GLP-1 trade in the pharmaceutical s",
      "url": "https://finnhub.io/api/news?id=2a97c38ed56329e72c1038cab397f0480622db64fd59451ea74acc8fdd3bed0d"
    },
    {
      "headline": "Metsera: Long-Acting MET-097i And Product Differentiation Nets Pfizer Acquisition",
      "source": "SeekingAlpha",
      "datetime": 1758556556,
      "summary": "Metsera, Inc. is being acquired by Pfizer Inc. for up to $7.3 billion, driven by its innovative obesity drug pipeline. Click to read why MTSR is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=672546e5b973028908d86da56bd98a1fa63364fadd28e94952e97f8445426233"
    },
    {
      "headline": "Pfizer Jumps Back into the Weight-Loss Race With $4.9B Acquisition",
      "source": "Yahoo",
      "datetime": 1758554220,
      "summary": "Pfizer said it would buy a clinical stage biopharma company for up to $7 billion, as it eyes the lucrative weight-loss drug market currently dominated by Eli Lilly and Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=9b8c8de28a969383d59e5af39e03e393f1cff5e9dbef571b046ed9e90d96a1d0"
    },
    {
      "headline": "Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion",
      "source": "Yahoo",
      "datetime": 1758552840,
      "summary": "The deal returns the drug-maker to the growing market for obesity drugs after scrapping an experimental weight-loss pill.",
      "url": "https://finnhub.io/api/news?id=541cc41b589b3df8b4e2e82bbbf7d27b4f89c3a32b0b9c084930f3a935f31e7a"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-22",
      "description": "xslF345X05/form4-09222025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000009/xslF345X05/form4-09222025_040901.xml"
    },
    {
      "form": "4",
      "date": "2025-09-19",
      "description": "xslF345X05/form4-09192025_040901.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000007/xslF345X05/form4-09192025_040901.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142191.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000126238825000004/xslF345X05/wk-form4_1758142191.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142140.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000242/xslF345X05/wk-form4_1758142140.xml"
    },
    {
      "form": "4",
      "date": "2025-09-17",
      "description": "xslF345X05/wk-form4_1758142082.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000134082325000006/xslF345X05/wk-form4_1758142082.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}